A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

Exclusion Criteria

• •Prior treatment with mosunetuzumab or other CD20-directed bispecific antibodies
• •Prior treatment with polatuzumab vedotin
• •Current \> Grade 1 peripheral neuropathy
• •Prior use of any monoclonal antibody, radioimmunoconjugate or antibody-drug conjugate (ADC) within 4 weeks before first dose of study treatment
• •Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent (investigational or otherwise) within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to first dose of study treatment
• •Treatment with radiotherapy within 2 weeks prior to the first dose of study treatment
• •Autologous stem-cell transplantation (SCT) within 100 days prior to first study treatment administration
• •Prior treatment with chimeric antigen receptor T-cell (CAR-T) therapy within 30 days before first study treatment administration
• •Prior allogeneic SCT
• •Prior solid organ transplantation
• •Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
• •Patients with history of confirmed progressive multifocal leukoencephalopathy (PML)
• •Current or past history of central nervous system (CNS) lymphoma or CNS disease
• •History of autoimmune disease